USPTO serial 79278845
Serial No. 79278845
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 26, 2021
- Examiner
- MESSICK, TABITHA LEE
- Law office
- TMEG LAW OFFICE 104
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with Serial No. 79278845?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
CN
CN
Taizhou, Jiangsu, CN
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
CN
Other trademarks owned by ASCENTAGE PHARMA (SUZHOU) CO., LTD.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kathryn E. Smith
Kathryn E. Smith Wood Herron & Evans LLP600 Vine StreetSuite 2800Cincinnati, OH 45202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories; medicinal oil solutions for medical purposes; hemostatic paste for medical purposes; bone paste for medical purpose; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candy, medicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic preparations adapted for medical use; mineral food supplements; nutritional supplements; drugs for human purposes, namely, medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablets, lozenges, chews, gels, fast dispersing dosage forms, films, ovules, sprays, buccal and mucoadhesive patches for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bulk drugs, namely, active pharmaceutical ingredients in the nature of drug delivery agents in the form of tablets, lozenges, chews, gels, fast dispersing dosage forms, films, ovules, sprays, buccal and mucoadhesive patches that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, kinase inhibitors and senolytic drugs; prescription drugs for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease medical purposes; chemical preparations for pharmaceutical or medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of injectables for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancer, tumors, blood-related diseases, infectious diseases, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for medical purposes, namely, active pharmaceutical ingredients in the nature of drug delivery agents in the form of powders, liquids, and capsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; chemical preparations for medical purposes, namely, active pharmaceutical ingredients in the nature of drug delivery agents in the form of tablets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the nature of transdermal patches for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicines for dental purposes; chemical preparations for medical purposes for treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antibiotics; tablets for medical purposes in the nature of vitamin tablets | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Jiangsu Ascentage Pharma Inc.
- Other trademarks owned by Jiangsu Ascentage Pharma Inc.
- Other trademarks owned by Jiangsu Ascentage Pharma Inc.
- Other trademarks owned by ASCENTAGE PHARMA (SUZHOU) CO., LTD.
- Other trademarks in Class 005
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 23, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 26, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 7, 2025 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Aug 21, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 21, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 21, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 21, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 21, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 26, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 26, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 26, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 26, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Dec 26, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 26, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 26, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 26, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 23, 2021 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Nov 20, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 24, 2021 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| May 23, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 30, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 30, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 26, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 26, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 10, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 10, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 8, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 21, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 21, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 21, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 6, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 6, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 6, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 5, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 5, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 5, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 5, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 5, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 16, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 7, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 7, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 22, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 21, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 25, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 19, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 13, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |